Transfusion‑dependent low‑risk myelodysplastic patients receiving deferasirox: Long‑term follow‑up

Improta,Salvatore; Villa,Maria  Rosaria; Volpe,Antonio; Lombardi,Angela; Stiuso,Paola; Cantore,Nicola; Mastrullo,Lucia

doi:10.3892/ol.2013.1617

Transfusion‑dependent low‑risk myelodysplastic patients receiving deferasirox: Long‑term follow‑up

Authors:
- Salvatore Improta
- Maria Rosaria Villa
- Antonio Volpe
- Angela Lombardi
- Paola Stiuso
- Nicola Cantore
- Lucia Mastrullo
View Affiliations

Affiliations: Hematology Division, P.O. San Gennaro ASL NA1 Centro, Naples I‑80136, Italy, Hematology Division, A.O.R.N. San G. Moscati, Avellino I‑83100, Italy, Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples I-80138, Italy
Published online on: October 10, 2013 https://doi.org/10.3892/ol.2013.1617
Pages: 1774-1778

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis that results in peripheral cytopenias. Anemia is the most common symptom of MDS and the majority of patients become transfusion‑dependent with the risk of iron overload, which may lead to cardiac, hepatic and endocrine complications. Deferasirox is an orally available iron chelator administered once‑daily in transfusion‑dependent patients with various chronic anemias. Its efficacy has been established in controlled clinical trials. In the present study, we describe our experience with 55 consecutive MDS patients [International Prognostic Scoring System risk score of low (n=32) or intermediate‑1 (n=23)] treated with deferasirox in a routine clinical setting following Consensus Guidelines on Iron Chelation Therapy. According to WHO classifications, patients had refractory anemia (n=30), refractory anemia with ringed sideroblasts (n=16), refractory cytopenia with multilineage dysplasia (n=8) or refractory cytopenia with multilineage dysplasia and ringed sideroblasts (n=1). The median monthly transfusion requirement at baseline was 3 units. Patients received a starting dosage of 10 mg/kg/day, subsequently titrated according to serum ferritin (SF) levels which were measured monthly. Safety assessment included monitoring of liver and renal parameters and recording adverse events (AE) during treatment. At the baseline, the mean ± SD SF level was 2,362±172 ng/ml and after 24 months, the mean ± SD decrease in SF was 1,679±209 ng/ml. Sixteen patients had sustained hematological improvement meeting International Working Group 2006 criteria. One patient became transfusion‑independent. No severe AE were reported. In conclusion, deferasirox therapy was effective and safe in reducing transfusional iron overload and it reduces transfusion requirement in a subset of patients.

View Figures

View References

1	Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U and Gattermann N: Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res. 36:1067–1070. 2012.PubMed/NCBI
2	Dreyfus F: The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev. 22(Suppl 2): S29–S34. 2008. View Article : Google Scholar : PubMed/NCBI
3	Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 23:7594–7603. 2005. View Article : Google Scholar
4	Delea TE, Hagiwara M and Phatak PD: Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 25:139–147. 2009. View Article : Google Scholar
5	Toma A, Fenaux P, Dreyfus F and Cordonnier C: Infections in myelodysplastic syndromes. Haematologica. 97:1459–1470. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rose C, Brechignac S, Vassilief D, et al: Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res. 34:864–870. 2010.PubMed/NCBI
7	Komrokji RS, Al Ali NH, Padron E, Lancet JE and List AF: Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt Cancer Center. Blood (ASH Annual Meeting Abstracts). 118:27762011.
8	Lyons RM, Marek BJ, Paley C, et al: Relationship between chelation and clinical outcomes in 600 lower-risk MDS ratients: registry analysis at 36 months. Blood (ASH Annual Meeting Abstracts). 120:38002012.
9	de Swart L, Smith A, Fenaux P, et al: Early mortality in 1000 newly diagnosed MDS patients with low- and intermediate-1 risk MDS in the European Leukemianet MDS (EUMDS) registry. Blood (ASH Annual Meeting Abstracts). 120:38302012.
10	Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, et al: Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 34:1576–1588. 2010. View Article : Google Scholar : PubMed/NCBI
11	Arboretti R, Tognoni G and Alberti D: Italian Colaborative Group on Thalassarmia Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol. 56:915–922. 2001. View Article : Google Scholar
12	Cappellini MD and Piga A: Current status in iron chelation in hemoglobinopathies. Curr Mol Med. 8:663–674. 2008. View Article : Google Scholar : PubMed/NCBI
13	Galanello R, Campus S and Origa R: Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 8:123–134. 2012. View Article : Google Scholar : PubMed/NCBI
14	List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al: Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion dependent patients with myelodysplastic syndrome. J Clin Oncol. 30:2134–2139. 2012. View Article : Google Scholar : PubMed/NCBI
15	Gattermann N, Finelli C, Della Porta M, et al: Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 97:1364–1371. 2012. View Article : Google Scholar : PubMed/NCBI
16	Angelucci E, Santini V, Di Tucci AA, et al: Deferasirox chelation therapy in transfusion dependent MDS patients. Final report from the GIMEMA MDS0306 prospective trial. Blood (ASH Annual Meeting Abstracts). 120:4252012.
17	Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D’Auria F, et al: Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res. 35:566–570. 2011. View Article : Google Scholar : PubMed/NCBI
18	Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 108:419–425. 2006. View Article : Google Scholar : PubMed/NCBI
19	Gattermann N, Finelli C, Della Porta M, et al: Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 34:1143–1150. 2010.PubMed/NCBI
20	Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ and Antin JH: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 109:4586–4588. 2007. View Article : Google Scholar
21	Yahata T, Takanashi T, Muguruma Y, Ibrahim AA, Matsuzawa H, Uno T, Sheng Y, Onizuka M, Ito M, Kato S and Ando K: Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. Blood. 118:2941–2950. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S and Rachmilewitz EA: Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica. 95:1433–1434. 2010. View Article : Google Scholar : PubMed/NCBI
23	Messa E, Carturan S, Maffé C, Pautasso M, Bracco E, Roetto A, et al: Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 95:1308–1316. 2010. View Article : Google Scholar
24	Jensen PD, Jensen IM and Ellegaard J: Desferoxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol. 80:121–124. 1992. View Article : Google Scholar : PubMed/NCBI